Trial Profile
An International Multi-center Phase 2 Study to Evaluate the Safety and Efficacy of Sequential Melphalan Hydrochloride for Injection for Use With the Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable Hepatocellular Carcinoma
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 21 Dec 2017
Price :
$35
*
At a glance
- Drugs Melphalan (Primary) ; Sorafenib
- Indications Cholangiocarcinoma; Liver cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Delcath Systems
- 14 Dec 2017 Status changed from recruiting to withdrawn prior to enrolment.
- 14 Apr 2015 New source identified and integrated (ClinicalTrials.gov record: NCT02406508)
- 07 Apr 2015 According to a Delcath Systems media release, Montefiore Medical Center in the Bronx, New York has joined the U.S Phase 2 HCC study and is now open for patient enrollment. The Company now has two centers participating in the U.S.